|Day Low/High||27.78 / 28.25|
|52 Wk Low/High||25.04 / 41.55|
Qiagen (Nasdaq:QGEN) has been downgraded by TheStreet Ratings from from a buy to hold.
Qiagen's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Qiagen (Nasdaq:QGEN) is trading at unusually high volume Monday with 5.7 million shares changing hands. It is currently at four times its average daily volume and trading up 56 cents (+3%).
The Government of Rwanda, together with QIAGEN N.V.
IBM, AOL, Texas Instruments and other large companies serve as mentors -- and potential acquirers -- at the country's 1,400 business incubators.
FDA approves 2 genetic tests from Hologic to assess the risks of cervical cancer
Hercules Offshore, Lions Gate, Nvidia and ProLogis are downgraded; Qiagen is upgraded.
The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.
Amid robust M&A, the unraveling of Shanghai speculation is having a limited global effect -- for now.
The Dutch molecular diagnostic company will pay $1.6 billion for its U.S. rival.
Don't make long-term commitments on either side of the market ahead of the FOMC meeting.
A very busy JPMorgan Healthcare Conference offers up some with good news and others in denial.
The prize awarded to two RNAi researchers is likely good for investor confidence in the sector.
Cramer believes the stock is headed to $100.
ING's Internet unit is driving growth at the Dutch financial services company, and the stock's likely to head higher.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.